ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium
Authors
Lavanya Jain, Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Maria Khrestian, Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Shane Formica, Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Elizabeth D. Tuason, Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Jagan A. Pillai, Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.
Stephen Rao, Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.
Odinachi Oguh, Cleveland Clinic Lou Ruvo Center for Brain Health-Las Vegas, Cleveland Clinic, Las Vegas, Nevada, USA.
Carol F. Lippa, Cleveland Clinic Lou Ruvo Center for Brain Health-Las Vegas, Cleveland Clinic, Las Vegas, Nevada, USA.
Oscar L. Lopez, Cognitive Disorders & Comprehensive Alzheimer's Disease Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Sarah B. Berman, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Debby W. Tsuang, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA.
Cyrus P. Zabetian, Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington, USA.
David J. Irwin, Department of Neurology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA.
Douglas R. Galasko, Department of Neurosciences, University of California, San Diego, California, USA.
Irene Litvan, Department of Neurosciences, University of California, San Diego, California, USA.
Karen S. Marder, Columbia University Irving Medical Center, New York, New York, USA.
Lawrence S. Honig, Department of Neurosciences, University of California, San Diego, California, USA.
Jori E. Fleisher, Department of Neurological Sciences, Rush Medical College, Chicago, Illinois, USA.
James E. Galvin, Department of Neurology, Comprehensive Center for Brain Health, University of Miami Miller School of Medicine, Miami, Florida, USA.
Andrea C. Bozoki, Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA.
Angela S. Taylor, Lewy Body Dementia Association, Lilburn, Georgia, USA.
Marwan N. Sabbagh, Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA.
James B. Leverenz, Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.
Lynn M. Bekris, Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract
INTRODUCTION: The National Institute on Aging - Alzheimer's Association (NIA-AA) ATN research framework proposes to use biomarkers for amyloid (A), tau (T), and neurodegeneration (N) to stage individuals with AD pathological features and track changes longitudinally. The overall aim was to utilize this framework to characterize pre-mortem ATN status longitudinally in a clinically diagnosed cohort of dementia with Lewy bodies (DLB) and to correlate it with the post mortem diagnosis. METHODS: The cohort was subtyped by cerebrospinal fluid (CSF) ATN category. A subcohort had longitudinal data, and a subgroup was neuropathologically evaluated. RESULTS: We observed a significant difference in Aβ after 12 months in the A+T- group. Post mortem neuropathologic analyses indicated that most of the p-Tau 181 positive (T+) cases also had a high Braak stage. DISCUSSION: This suggests that DLB patients who are A+ but T- may need to be monitored to determine whether they remain A+ or ever progress to T positivity. HIGHLIGHTS: Some A+T- DLB subjects transition from A+ to negative after 12-months. Clinically diagnosed DLB with LBP-AD (A+T+) maintain their positivity. Clinically diagnosed DLB with LBP-AD (A+T+) maintain their positivity. Monitoring of the A+T- sub-type of DLB may be necessary.
Publication Date
9-23-2023
Publication Title
Alzheimer's & dementia : the journal of the Alzheimer's Association
Digital Object Identifier (DOI)
10.1002/alz.13398
Recommended Citation
Jain, Lavanya; Khrestian, Maria; Formica, Shane; Tuason, Elizabeth D.; Pillai, Jagan A.; Rao, Stephen; Oguh, Odinachi; Lippa, Carol F.; Lopez, Oscar L.; Berman, Sarah B.; Tsuang, Debby W.; Zabetian, Cyrus P.; Irwin, David J.; Galasko, Douglas R.; Litvan, Irene; Marder, Karen S.; Honig, Lawrence S.; Fleisher, Jori E.; Galvin, James E.; Bozoki, Andrea C.; Taylor, Angela S.; Sabbagh, Marwan N.; Leverenz, James B.; and Bekris, Lynn M., "ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium" (2023). Neurology. 1709.
https://scholar.barrowneuro.org/neurology/1709
